Tanvex BioPharma, Inc.
6541
Rank in Stocks
#16056
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a... Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
Share Price
$0.86880707
Last synced: 2026-11-10
Market Cap
$230.23M
Change (1 day)
-2.06%
Change (1 year)
-50.77%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Tanvex BioPharma, Inc. (6541)
Category
Healthcare
EPS for Tanvex BioPharma, Inc. (6541)
EPS as of June 2026 TTM: $-0.17
According to Tanvex BioPharma, Inc.'s latest financial reports, its current EPS (TTM) is $-0.17. At the end of 2025 the company had an EPS of $-0.20, an increase over its 2024 EPS of $-0.27.
EPS history for Tanvex BioPharma, Inc. from 2013 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.17 | -13.70% |
| 2025 | $-0.20 | -27.99% |
| 2024 | $-0.27 | -49.32% |
| 2023 | $-0.54 | 21.09% |
| 2022 | $-0.44 | -11.25% |
| 2021 | $-0.50 | -38.13% |
| 2020 | $-0.80 | -7.97% |
| 2019 | $-0.87 | 7.22% |
| 2018 | $-0.82 | 17.08% |
| 2017 | $-0.70 | 21.80% |
| 2016 | $-0.57 | 12.58% |
| 2015 | $-0.51 | 18.64% |
| 2014 | $-0.43 | 28.67% |
| 2013 | $-0.33 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -9,173.00% |
US
|
|
| $-7.07 | 3,996.18% |
US
|
|
| $-5.29 | 2,964.89% |
AU
|
|
| $12.88 | -7,562.40% |
BE
|
|
| $21.56 | -12,591.31% |
NL
|
Questions about Tanvex BioPharma, Inc.'s earnings per share (EPS)
What is Tanvex BioPharma, Inc.'s earnings per share (EPS)?
Tanvex BioPharma, Inc.'s earnings per share (EPS) over the last twelve months is $-0.17, as of Jun 2026.
What was Tanvex BioPharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Tanvex BioPharma, Inc.'s earnings per share (EPS) was $-0.20, compared with $-0.27 in 2024.
How has Tanvex BioPharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Tanvex BioPharma, Inc.'s earnings per share (EPS) was highest in 2025 ($-0.20) and lowest in 2020 ($-0.80).
How does Tanvex BioPharma, Inc.'s earnings per share (EPS) compare with similar companies?
Tanvex BioPharma, Inc.'s earnings per share (EPS) ($-0.17) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.